{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-128088","form_type":"8-K/A","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2024-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.243396+00:00","generated_at":"2026-05-29T03:49:49.294424+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gilead appoints Dietmar Berger as Chief Medical Officer effective Jan 2, 2025","bullets":["Dietmar Berger, MD PhD, will become Chief Medical Officer and member of senior leadership team on January 2, 2025.","Berger succeeds Merdad Parsey, MD PhD, who will stay as Senior Advisor through Q1 2025.","Berger previously served as Chief Medical Officer and Global Head of Development at Sanofi.","Berger will oversee Gilead's virology, oncology, inflammation portfolio and global Development/Medical Affairs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-128088","json":"https://secwatch.observer/filing/0001104659-24-128088.json","markdown":"https://secwatch.observer/filing/0001104659-24-128088.md","text":"https://secwatch.observer/filing/0001104659-24-128088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000110465924128088/0001104659-24-128088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000110465924128088/tm2430889d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:49:49.294424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}